This webcast discusses how drug safety teams can use dynamic visual analytics to uncover safety issues earlier. All the while, complying with extremely complex and ever-evolving regulatory requirements.
This webcast discusses how medical monitors can leverage guided visual analytics to find and act on the right issues quickly without sifting through mounds of clinical data.
Understand the benefits and challenges of each modality used in clinical trials today, items to consider when choosing an eCOA modality, as well as tips for successful eCOA modality selection.
In this webinar, INC Research/inVentiv Health experts discuss the factors that sponsors must take into account as they design and execute clinical trials in this space, beginning with a review of the immunotherapy landscape.
The webinar focuses issues and bottlenecks that contribute to delays that are outside of the CRA control.
The webinar will focus on these issues and the competitive edge metrics provide those organizations engaged in conducting clinical trials.
This webinar covers the study assessing sponsor and CRO experience, practices and improvement areas associated with investigative site identification, feasibility, selection and study startup.
Presenters: Naor Chazan, Director of Marketing (but no longer with the company, FYI) and Sandra “SAM” Sather, Quality and Regulatory, TrialConsent) CRF Health's State of eConsent 2017 Report surveyed 100 biotech, pharmaceutical, CRO, and IRB organizations who shared their opinions on Electronic Informed Consent (eConsent). During this webinar, industry expert, Sandra "Sam" Sather, Regulatory and Quality Lead for TrialConsentTM at CRF Health, discusses the results.
The number of oncology clinical trials has increased exponentially in recent years, putting ever more pressure on increasing clinical trial efficiency by reducing costs and timelines. Patient recruitment swallows 40% of trial costs, yet only 10–17% of studies enroll on time and approximately 11% of sites in any given study fail to enroll a single patient.
Recent successes in the treatment of cancer have led to more complex trials such as master protocols using basket (or bucket) and umbrella designs. These combination designs, with or without cancer immunotherapy treatments, require careful deliberations to optimize dosages and include multiple tumor types in expansion cohorts. Making informed decisions in study design for your basket/bucket or umbrella trials requires relevant and timely evidence-based data.
|
|
|
|
|
|
|
|
|